{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:12:13Z","timestamp":1792793533470,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"ECOG-ACRIN Cancer Research Group","id":[{"id":"https:\/\/ror.org\/00d3km654","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Memorial Sloan Kettering Cancer Center Support","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["U10CA180820"],"award-info":[{"award-number":["U10CA180820"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["U10CA180794"],"award-info":[{"award-number":["U10CA180794"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["UG1CA233302"],"award-info":[{"award-number":["UG1CA233302"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["UG1CA233290"],"award-info":[{"award-number":["UG1CA233290"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["UG1CA233341"],"award-info":[{"award-number":["UG1CA233341"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["UG1CA233329"],"award-info":[{"award-number":["UG1CA233329"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["UG1CA233180"],"award-info":[{"award-number":["UG1CA233180"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["NCI P30 CA142543"],"award-info":[{"award-number":["NCI P30 CA142543"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1093\/annonc\/mdz291","type":"journal-article","created":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T08:10:49Z","timestamp":1566634249000},"page":"1821-1830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":140,"title":["Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric\/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q"],"prefix":"10.1016","volume":"30","author":[{"given":"K.L.","family":"Jhaveri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.V.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Makker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-W.","family":"Luoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.P.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Zwiebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Sharon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.M.","family":"McShane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.V.","family":"Rubinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Patton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.M.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.R.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.A.","family":"Conley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.L.","family":"Arteaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.N.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.J.","family":"O\u2019Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.P.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.T.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4785","key":"10.1093\/annonc\/mdz291_bb0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"issue":"4905","key":"10.1093\/annonc\/mdz291_bb0015","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"issue":"31","key":"10.1093\/annonc\/mdz291_bb0020","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"JCO"},{"issue":"9742","key":"10.1093\/annonc\/mdz291_bb0025","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"10.1093\/annonc\/mdz291_bb0030","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1093\/annonc\/mdz291_bb0035","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1093\/annonc\/mdz291_bb0040","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab\u2013mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1093\/annonc\/mdz291_bb0045","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1093\/annonc\/mdz291_bb0050","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1093\/annonc\/mdz291_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-013-0252-z","article-title":"HER2-positive gastric cancer","volume":"17","author":"Boku","year":"2014","journal-title":"Gastric Cancer"},{"issue":"10","key":"10.1093\/annonc\/mdz291_bb0060","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1093\/annonc\/mds104","article-title":"Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis","volume":"23","author":"Janjigian","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdz291_bb0065","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdz291_bb0070","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"issue":"19","key":"10.1093\/annonc\/mdz291_bb0075","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"issue":"7447","key":"10.1093\/annonc\/mdz291_bb0080","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1093\/annonc\/mdz291_bb0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2007.09.007","article-title":"An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"108","author":"Grushko","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdz291_bb0090","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"issue":"269","key":"10.1093\/annonc\/mdz291_bb0095","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"issue":"5","key":"10.1093\/annonc\/mdz291_bb0100","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1093\/annonc\/mdz291_bb0105","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.ctrv.2014.02.008","article-title":"HER2 aberrations in cancer: implications for therapy","volume":"40","author":"Yan","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1093\/annonc\/mdz291_bb0110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12920-017-0271-4","article-title":"Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing","volume":"10","author":"Cheng","year":"2017","journal-title":"BMC Med Genomics"},{"issue":"6","key":"10.1093\/annonc\/mdz291_bb0115","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdz291_bb0120","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1097\/JTO.0b013e3181ea510a","article-title":"Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients","volume":"5","author":"Al-Saad","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdz291_bb0125","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/modpathol.2013.201","article-title":"Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome","volume":"27","author":"Schneider","year":"2014","journal-title":"Mod Pathol"},{"issue":"15","key":"10.1093\/annonc\/mdz291_bb0130","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2005.03.4827","article-title":"HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients","volume":"24","author":"Morrison","year":"2006","journal-title":"JCO"},{"issue":"2","key":"10.1093\/annonc\/mdz291_bb0135","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40291-013-0024-9","article-title":"HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies","volume":"17","author":"English","year":"2013","journal-title":"Mol Diagn Ther"},{"issue":"6","key":"10.1093\/annonc\/mdz291_bb0140","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdz291_bb0145","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jmoldx.2016.10.007","article-title":"Analytical validation of the next-generation sequencing assay for a nationwide signal-finding clinical trial: molecular analysis for therapy choice clinical trial","volume":"19","author":"Lih","year":"2017","journal-title":"J Mol Diagn"},{"issue":"3","key":"10.1093\/annonc\/mdz291_bb0150","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1158\/1078-0432.CCR-17-1597","article-title":"Validation of immunohistochemical assays for integral biomarkers in the NCI-MATCH EAY131 clinical trial","volume":"24","author":"Khoury","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1093\/annonc\/mdz291_bb0155","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdz291_bb0160","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"issue":"24","key":"10.1093\/annonc\/mdz291_bb0165","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1200\/JCO.2018.77.9777","article-title":"Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II Basket Trial","volume":"36","author":"Li","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdz291_bb0170","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1093\/annonc\/mdz291_bb0175","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdz291_bb0180","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaad.2015.03.021","article-title":"Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC","volume":"72","author":"Sekulic","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"7691","key":"10.1093\/annonc\/mdz291_bb0185","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"issue":"20","key":"10.1093\/annonc\/mdz291_bb0190","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2017.73.0143","article-title":"AKT inhibition in solid tumors with AKT1 mutations","volume":"35","author":"Hyman","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdz291_bb0195","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdz291_bb0200","article-title":"Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): results from a phase II basket trial","author":"Li","year":"2019","journal-title":"Presented at the Annual ASCO Meeting"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdz291_bb0205","article-title":"Updated results of phase 1 study of DS-8201a in patients with HER2 expressing non-breast, non-gastric malignancies","volume":"28","author":"Tsurutani","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdz291_bb0210","article-title":"A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2amplified cancers","author":"Li","year":"2018","journal-title":"In Presented at the Annual ASCO meeting"},{"issue":"4","key":"10.1093\/annonc\/mdz291_bb0215","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"JCO"},{"issue":"7","key":"10.1093\/annonc\/mdz291_bb0220","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JOP.18.00206","article-title":"HER2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update Summary","volume":"14","author":"Wolff","year":"2018","journal-title":"JOP"},{"key":"10.1093\/annonc\/mdz291_bb0225","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","article-title":"The genomic landscape of endocrine-resistant advanced breast cancers","volume":"34","author":"Razavi","year":"2018","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1093\/annonc\/mdz291_bb0230","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jmoldx.2016.09.010","article-title":"Next-generation assessment of human epidermal growth factor receptor 2 (ERBB2) amplification status: clinical validation in the context of a hybrid capture-based, comprehensive solid tumor genomic profiling assay","volume":"19","author":"Ross","year":"2017","journal-title":"J Mol Diagn"},{"issue":"1","key":"10.1093\/annonc\/mdz291_bb0235","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.molonc.2015.09.002","article-title":"High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy","volume":"10","author":"Nuciforo","year":"2016","journal-title":"Mol Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdz291_bb0240","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1158\/1078-0432.CCR-18-3389","article-title":"Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer","volume":"25","author":"Siravegna","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1093\/annonc\/mdz291_bb0245","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1158\/1078-0432.CCR-09-1735","article-title":"Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes","volume":"15","author":"Mittendorf","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1093\/annonc\/mdz291_bb0250","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1158\/1535-7163.MCT-17-0296","article-title":"Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells","volume":"17","author":"Li","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1093\/annonc\/mdz291_bb0255","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1158\/2159-8290.CD-18-0598","article-title":"EGFR and MET amplifications determine response to HER2 inhibition in ERBB2-amplified esophagogastric cancer","volume":"9","author":"Sanchez-Vega","year":"2019","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1093\/annonc\/mdz291_bb0260","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1373\/clinchem.2016.261834","article-title":"Next generation sequencing of circulating cell-free DNA for evaluating mutations and gene amplification in metastatic breast cancer","volume":"63","author":"Page","year":"2017","journal-title":"Clin Chem"},{"issue":"2","key":"10.1093\/annonc\/mdz291_bb0265","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2016.70.2712","article-title":"MARIANNE: impact on current treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer and implications for the future","volume":"35","author":"Jhaveri","year":"2017","journal-title":"JCO"}],"updated-by":[{"DOI":"10.1016\/j.annonc.2021.05.797","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000}}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420325904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420325904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/advance-article-pdf\/doi\/10.1093\/annonc\/mdz291\/29217130\/mdz291.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/30\/11\/1821\/31604865\/mdz291.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/30\/11\/1821\/31604865\/mdz291.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T14:09:26Z","timestamp":1668694166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753420325904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0923753420325904"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdz291","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric\/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1093\/annonc\/mdz291","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}